{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"AVIR","limit":50},"count":50,"signals":[{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"of the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2026-03-05","accession":"0001193125-26-094159","full_text":"https://origin.rootz.global/static/filing/0001193125-26-094159.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"s product candidate fails in clinical development, does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed. A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for and successfully commercialize the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV. We currently ha","filed_date":"2026-03-05","accession":"0001193125-26-094159","full_text":"https://origin.rootz.global/static/filing/0001193125-26-094159.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":83,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. We currently conduct, and may in the future, conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in foreign","filed_date":"2026-03-05","accession":"0001193125-26-094159","full_text":"https://origin.rootz.global/static/filing/0001193125-26-094159.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"of the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2025-11-12","accession":"0001193125-25-277815","full_text":"https://origin.rootz.global/static/filing/0001193125-25-277815.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":47,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in foreign l","filed_date":"2025-11-12","accession":"0001193125-25-277815","full_text":"https://origin.rootz.global/static/filing/0001193125-25-277815.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"of the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2025-08-07","accession":"0000950170-25-105123","full_text":"https://origin.rootz.global/static/filing/0000950170-25-105123.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":47,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in foreign l","filed_date":"2025-08-07","accession":"0000950170-25-105123","full_text":"https://origin.rootz.global/static/filing/0000950170-25-105123.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"of the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2025-05-12","accession":"0000950170-25-069367","full_text":"https://origin.rootz.global/static/filing/0000950170-25-069367.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":47,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in foreign l","filed_date":"2025-05-12","accession":"0000950170-25-069367","full_text":"https://origin.rootz.global/static/filing/0000950170-25-069367.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"ntment of KPMG LLP as our independent registered public accounting firm for the year ending December31, 2025 | | FOR | | | 3.To approve, on an advisory (non-binding) basis, the compensation of our named executive officers | | FOR | | These items of business are more fully described in the Proxy Statement accompanying this Notice of Annual Meeting. We will also consider and transact any other business that may prope","filed_date":"2025-04-29","accession":"0001193125-25-104019","full_text":"https://origin.rootz.global/static/filing/0001193125-25-104019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"of the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2025-03-06","accession":"0000950170-25-034808","full_text":"https://origin.rootz.global/static/filing/0000950170-25-034808.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"s product candidate fails in clinical development, does not receive regulatory approval or is not successfully commercialized, or is significantly delayed in doing so, our business will be harmed. A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for and successfully commercialize the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV. We currently ha","filed_date":"2025-03-06","accession":"0000950170-25-034808","full_text":"https://origin.rootz.global/static/filing/0000950170-25-034808.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":83,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in foreign l","filed_date":"2025-03-06","accession":"0000950170-25-034808","full_text":"https://origin.rootz.global/static/filing/0000950170-25-034808.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in foreign l","filed_date":"2024-11-07","accession":"0000950170-24-123447","full_text":"https://origin.rootz.global/static/filing/0000950170-24-123447.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"of the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2024-08-07","accession":"0000950170-24-092914","full_text":"https://origin.rootz.global/static/filing/0000950170-24-092914.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in foreign l","filed_date":"2024-08-07","accession":"0000950170-24-092914","full_text":"https://origin.rootz.global/static/filing/0000950170-24-092914.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"of the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2024-05-14","accession":"0000950170-24-059699","full_text":"https://origin.rootz.global/static/filing/0000950170-24-059699.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (\"US\"). The FDA may not accept data from trials conducted in foreign","filed_date":"2024-05-14","accession":"0000950170-24-059699","full_text":"https://origin.rootz.global/static/filing/0000950170-24-059699.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"through Day 29 in patients receiving bemnifosbuvir as a monotherapy. Secondary endpoints include COVID-19 complications, medically attended visits, symptom rebound/relapse and viral load rebound. Enrollment of patients in the 21 SUNRISE-3 study was completed in March 2024. We anticipate announcing the results of the SUNRISE-3 study in the second half of 2024. In parallel with conducting SUNRISE-3,","filed_date":"2024-04-26","accession":"0000950170-24-049178","full_text":"https://origin.rootz.global/static/filing/0000950170-24-049178.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":31,"context":"REGISTERED PUBLIC ACCOUNTING FIRM | 10 | | | REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 12 | | | PROPOSAL 3 APPROVAL ON AN ADVISORY (NON-BINDING) BASIS OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS | 13 | | | CORPORATE GOVERNANCE | 14 | | | COMMITTEES OF THE BOARD | 17 | | | EXECUTIVE OFFICERS | 20 | | | EXECUTIVE OFFICER AND DIRECTOR COMPENSATION | 21 | | | EQUITY COMPENSATION","filed_date":"2024-04-26","accession":"0000950170-24-049178","full_text":"https://origin.rootz.global/static/filing/0000950170-24-049178.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":30,"context":"of the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2024-02-28","accession":"0000950170-24-022226","full_text":"https://origin.rootz.global/static/filing/0000950170-24-022226.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"e product candidates fail in clinical development, do not receive regulatory approval or are not successfully commercialized, or are significantly delayed in doing so, our business will be harmed. A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for and successfully commercialize one or more bemnifosbuvir COV19 product candidates and the combination of bemnifosb","filed_date":"2024-02-28","accession":"0000950170-24-022226","full_text":"https://origin.rootz.global/static/filing/0000950170-24-022226.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":85,"context":"ious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their iv regulatory approval, limit their commercial potential or result in significant negative consequences. We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (\"US\"). The FDA may not accept data from trials conducted in foreign","filed_date":"2024-02-28","accession":"0000950170-24-022226","full_text":"https://origin.rootz.global/static/filing/0000950170-24-022226.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":24,"context":"g Administration (“FDA”) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. • Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2023-11-08","accession":"0000950170-23-061213","full_text":"https://origin.rootz.global/static/filing/0000950170-23-061213.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. • We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in","filed_date":"2023-11-08","accession":"0000950170-23-061213","full_text":"https://origin.rootz.global/static/filing/0000950170-23-061213.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"g Administration (“FDA”) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. • Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2023-08-08","accession":"0000950170-23-039920","full_text":"https://origin.rootz.global/static/filing/0000950170-23-039920.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. • We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in","filed_date":"2023-08-08","accession":"0000950170-23-039920","full_text":"https://origin.rootz.global/static/filing/0000950170-23-039920.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"g Administration (“FDA”) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. • Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2023-05-08","accession":"0000950170-23-018869","full_text":"https://origin.rootz.global/static/filing/0000950170-23-018869.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. • We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in","filed_date":"2023-05-08","accession":"0000950170-23-018869","full_text":"https://origin.rootz.global/static/filing/0000950170-23-018869.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"TION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | 12 | | | REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 14 | | | PROPOSAL 3 --- APPROVAL OF THE COMPENSATION OF NAMED EXECUTIVE OFFICERS BY ADVISORY (NON-BINDING) VOTE | 15 | | | CORPORATE GOVERNANCE | 16 | | | COMMITTEES OF THE BOARD | 20 | | | EXECUTIVE OFFICERS | 23 | | | COMPENSATION DISCUSSION AND ANALYSIS | 24 | |","filed_date":"2023-04-28","accession":"0000950170-23-015773","full_text":"https://origin.rootz.global/static/filing/0000950170-23-015773.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"g Administration (“FDA”) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable. • Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process. We may encounter substantial delays and costs in our clinical trials, or may not be able to conduct or complete our","filed_date":"2023-02-28","accession":"0000950170-23-005186","full_text":"https://origin.rootz.global/static/filing/0000950170-23-005186.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"e product candidates fail in clinical development, do not receive regulatory approval or are not successfully commercialized, or are significantly delayed in doing so, our business will be harmed. A substantial portion of our business and future success depends on our ability to develop, obtain regulatory approval for and successfully commercialize one or more bemnifosbuvir COV19 product candidates and the combination of bemnifosb","filed_date":"2023-02-28","accession":"0000950170-23-005186","full_text":"https://origin.rootz.global/static/filing/0000950170-23-005186.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":51,"context":"ious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their iv regulatory approval, limit their commercial potential or result in significant negative consequences. • We currently conduct and may in the future conduct clinical trials of our product candidates in sites outside the United States (US). The FDA may not accept data from trials conducted in","filed_date":"2023-02-28","accession":"0000950170-23-005186","full_text":"https://origin.rootz.global/static/filing/0000950170-23-005186.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":52,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. ii • We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the United States, and the FDA may","filed_date":"2022-11-07","accession":"0000950170-22-022699","full_text":"https://origin.rootz.global/static/filing/0000950170-22-022699.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":52,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. ii • We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the United States, and the FDA may","filed_date":"2022-08-08","accession":"0000950170-22-015570","full_text":"https://origin.rootz.global/static/filing/0000950170-22-015570.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":47,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. ii • We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the United States, and the FDA may","filed_date":"2022-05-10","accession":"0000950170-22-008732","full_text":"https://origin.rootz.global/static/filing/0000950170-22-008732.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":22,"context":"TING OF STOCKHOLDERS | | | 3 | | | | PROPOSAL 1 ELECTION OF DIRECTORS | | | 7 | | | | PROPOSAL 2 ADVISORY (NON-BINDING) VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF NAMED EXECUTIVE OFFICERS | | | 12 | | | | PROPOSAL 3 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | | | 13 | | | | REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | | | 1","filed_date":"2022-04-29","accession":"0001193125-22-134263","full_text":"https://origin.rootz.global/static/filing/0001193125-22-134263.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_concentration","strength":100,"match_count":1,"context":"e product candidates fail in clinical development, do not receive regulatory approval or are not successfully commercialized, or are significantly delayed in doing so, our business will be harmed. A substantial portion of our business and future success depends on our ability to identify and develop a bemnifosbuvir COV19 combination product candidate for the treatment of COVID-19 and to develop, obtain regulatory approval for and","filed_date":"2022-02-28","accession":"0001564590-22-007672","full_text":"https://origin.rootz.global/static/filing/0001564590-22-007672.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. | | | | | We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the United States, and the FDA may","filed_date":"2022-02-28","accession":"0001564590-22-007672","full_text":"https://origin.rootz.global/static/filing/0001564590-22-007672.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. | | | | | We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the United States, and the FDA may","filed_date":"2021-11-12","accession":"0001564590-21-056513","full_text":"https://origin.rootz.global/static/filing/0001564590-21-056513.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. | | | | | We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the United States, and the FDA may","filed_date":"2021-08-12","accession":"0001564590-21-044060","full_text":"https://origin.rootz.global/static/filing/0001564590-21-044060.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. | | | | | We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the United States, and the FDA may","filed_date":"2021-05-13","accession":"0001564590-21-027644","full_text":"https://origin.rootz.global/static/filing/0001564590-21-027644.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":34,"context":"entions and Broker Non-Votes | | | Proposal 1: Election of Directors | | The plurality of the votes cast. This means that the nominees receiving the highest number of affirmative FOR votes will be elected as Class I Directors. | | Votes withheld and broker non-votes will have no effect. | | | | | | | | Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm | | The affirmative vot","filed_date":"2021-04-29","accession":"0001193125-21-140382","full_text":"https://origin.rootz.global/static/filing/0001193125-21-140382.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. | | iii | | | We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the United States, and the FDA","filed_date":"2021-03-30","accession":"0001564590-21-016724","full_text":"https://origin.rootz.global/static/filing/0001564590-21-016724.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":46,"context":"serious adverse events, undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences. | | | | • | We currently conduct clinical trials, and may in the future choose to conduct additional clinical trials, of our product candidates in sites outside the United States, and the","filed_date":"2020-12-10","accession":"0001564590-20-056724","full_text":"https://origin.rootz.global/static/filing/0001564590-20-056724.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"programs and timelines. For example, our Phase 1/2A clinical trial of AT-787 for the treatment of HCV was paused until the clinical trial sites are able to re-open and we elect to resume patient enrollment, which has not yet occurred. Certain countries, including the United States, have begun the process of re-opening. However, any re-opening could take a significant amount of time, require addition","filed_date":"2020-10-26","accession":"0001193125-20-275997","full_text":"https://origin.rootz.global/static/filing/0001193125-20-275997.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"ill have taken resources away from other development programs and will not be able to recuperate the resources dedicated to developing AT-527 as a potential treatment for COVID-19, which could have a material adverse impact on our business. In addition, we anticipate announcing topline data from our Phase 2 trial after the expected closing of this offering. Our Phase 2 trial is subject to the risks related to clinical d","filed_date":"2020-10-26","accession":"0001193125-20-275997","full_text":"https://origin.rootz.global/static/filing/0001193125-20-275997.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":27,"context":"COMPENSATION** This section discusses the material components of the executive compensation program for our executive officers who are named in the 2019 Summary Compensation Table below. In 2019, our named executive officers and their positions were: | | | Jean-Pierre Sommadossi, Ph.D., Chairman and Chief Executive Officer; | | | | | Andrea Corcoran, Chief Financial Officer and Executive Vice President, Legal; an","filed_date":"2020-10-26","accession":"0001193125-20-275997","full_text":"https://origin.rootz.global/static/filing/0001193125-20-275997.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":27,"context":"cal programs and timelines. For example, our Phase 1/2A clinical trial of AT-787 for the treatment of HCV is currently paused until the clinical trial sites are able to re-open and resume patient enrollment. Certain 12 [Table of Contents](#toc) countries, including the United States, have begun the process of re-opening. However, any re-opening could take a significant amount of time, require addit","filed_date":"2020-10-09","accession":"0001193125-20-267199","full_text":"https://origin.rootz.global/static/filing/0001193125-20-267199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"AVIR","company":"Atea Pharmaceuticals, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":48,"context":"ill have taken resources away from other development programs and will not be able to recuperate the resources dedicated to developing AT-527 as a potential treatment for COVID-19, which could have a material adverse impact on our business. In addition, we anticipate announcing topline data from our Phase 2 trial after the expected closing of this offering. Our Phase 2 trial is subject to the risks related to clinical d","filed_date":"2020-10-09","accession":"0001193125-20-267199","full_text":"https://origin.rootz.global/static/filing/0001193125-20-267199.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"a0805928aeafc9999577616e78880637a8ba19e46f72bd6e248e8a965fcd1e0e","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"0cefb40943b0684e227871f4841ebaf98723e55910f806b3ad70f9f13d053cbc","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":133,"hourly_limit":500,"remaining":367,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}